This advisory introduces readers to digital therapeutics (DTx) and the benefits of their use in behavioral health. It describes the research, regulatory, and reimbursement implications for DTx as well as selection and implementation considerations.

The Executive Summary of this Treatment Improvement Protocol provides an overview on the use of the three Food and Drug Administration-approved medications used to treat opioid use disorder—methadone, naltrexone, and buprenorphine—and the other strategies and services needed to support recovery.

This Treatment Improvement Protocol (TIP) reviews the use of the three Food and Drug Administration (FDA)-approved medications used to treat OUD—methadone, naltrexone, and buprenorphine—and the other strategies and services needed to support recovery for people with OUD. This is a revision.

The EAP Prescription Drug Toolkit and Fact Sheets provide guidance related to counseling, referrals, and follow-up services (e.g., alternatives to prescription drugs, workplace drug misuse and relapse prevention, dangers of combined drug use, screenings, and evaluations before returning to work).

Designed for organizations that provide services to older adults, this toolkit offers information and materials to help understanding the issues associated with substance misuse and mental illness in older adults. The toolkit also contains materials to educate older adults.

This handbook provides guidance on using the web-based, multimedia tool Decisions in Recovery: Medications for Opioid Addiction. This handbook and the web-based tool offers information about medication-assisted treatment. Both resources help people living with opioid use disorder compare treatment options and discuss their preferences with a provider.

This guide explains prescription drug monitoring programs (PDMPs), and how they can enhance clinical decision making. The guide also explains how PDMP improves patient safety, while helping to decrease prescription drug misuse and unintentional overdose deaths.

This advisory defines attention deficit hyperactivity disorder in adults, and explains interactions with substance use disorders.